Viridian Current Deferred Revenue vs Cash Analysis

0K1R Stock

21.82 0.07 0.32%

Viridian Therapeutics financial indicator trend analysis is much more than just breaking down Viridian Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Viridian Therapeutics is a good investment. Please check the relationship between Viridian Therapeutics Current Deferred Revenue and its Cash accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Viridian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Viridian Stock please use our How to Invest in Viridian Therapeutics guide.

Current Deferred Revenue vs Cash

Current Deferred Revenue vs Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Viridian Therapeutics Current Deferred Revenue account and Cash. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Viridian Therapeutics' Current Deferred Revenue and Cash is -0.24. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Cash in the same time period over historical financial statements of Viridian Therapeutics, assuming nothing else is changed. The correlation between historical values of Viridian Therapeutics' Current Deferred Revenue and Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Viridian Therapeutics are associated (or correlated) with its Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash has no effect on the direction of Current Deferred Revenue i.e., Viridian Therapeutics' Current Deferred Revenue and Cash go up and down completely randomly.

Correlation Coefficient

-0.24

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Cash

Cash refers to the most liquid asset of Viridian Therapeutics, which is listed under current asset account on Viridian Therapeutics balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Viridian Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Viridian Therapeutics account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Most indicators from Viridian Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Viridian Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Viridian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Viridian Stock please use our How to Invest in Viridian Therapeutics guide.Selling General Administrative is likely to gain to about 99.7 M in 2024

	2021	2022	2023	2024 (projected)
Interest Expense	3K	486K	1.8M	1.9M
Depreciation And Amortization	620K	755K	522K	391.8K

Interest Expense Depreciation And Amortization

Viridian Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Assets	Net Tangible Assets
Total Assets		0.25	0.99	0.66	1.0	0.94	-0.4	-0.87	-0.98	0.61	0.93	0.69	0.57	1.0	-0.61	0.98	0.82	-0.65	0.85	0.99	0.85	1.0	-0.38	0.86	0.21	0.96
Short Long Term Debt Total	0.25		0.22	0.7	0.2	0.32	-0.12	0.11	-0.24	-0.11	0.11	-0.08	-0.17	0.25	0.15	0.34	0.45	0.06	0.28	0.27	0.71	0.25	0.7	0.28	0.12	0.31
Other Current Liab	0.99	0.22		0.62	0.99	0.91	-0.33	-0.84	-0.99	0.54	0.9	0.62	0.5	0.99	-0.66	0.97	0.83	-0.69	0.85	0.98	0.82	0.99	-0.41	0.85	0.08	0.94
Total Current Liabilities	0.66	0.7	0.62		0.63	0.7	-0.45	-0.45	-0.61	0.54	0.6	0.6	0.51	0.66	-0.2	0.67	0.43	-0.34	0.44	0.63	0.9	0.66	0.42	0.47	0.42	0.62
Total Stockholder Equity	1.0	0.2	0.99	0.63		0.94	-0.4	-0.88	-0.98	0.61	0.93	0.7	0.57	1.0	-0.63	0.98	0.81	-0.66	0.84	0.99	0.82	1.0	-0.42	0.85	0.2	0.95
Property Plant And Equipment Net	0.94	0.32	0.91	0.7	0.94		-0.57	-0.73	-0.89	0.56	0.81	0.68	0.53	0.94	-0.48	0.96	0.73	-0.46	0.7	0.93	0.84	0.94	-0.23	0.75	0.29	0.89
Current Deferred Revenue	-0.4	-0.12	-0.33	-0.45	-0.4	-0.57		0.21	0.34	-0.22	-0.24	-0.43	-0.35	-0.4	-0.08	-0.39	-0.02	-0.04	0.09	-0.33	-0.33	-0.39	-0.12	0.04	-0.43	-0.19
Net Debt	-0.87	0.11	-0.84	-0.45	-0.88	-0.73	0.21		0.82	-0.84	-0.98	-0.84	-0.79	-0.87	0.62	-0.79	-0.6	0.69	-0.78	-0.84	-0.6	-0.86	0.57	-0.77	-0.35	-0.85
Retained Earnings	-0.98	-0.24	-0.99	-0.61	-0.98	-0.89	0.34	0.82		-0.5	-0.88	-0.59	-0.45	-0.98	0.65	-0.96	-0.83	0.73	-0.87	-0.99	-0.82	-0.98	0.4	-0.87	-0.1	-0.93
Accounts Payable	0.61	-0.11	0.54	0.54	0.61	0.56	-0.22	-0.84	-0.5		0.81	0.96	0.98	0.61	-0.4	0.53	0.21	-0.46	0.45	0.55	0.48	0.6	-0.25	0.48	0.6	0.61
Cash	0.93	0.11	0.9	0.6	0.93	0.81	-0.24	-0.98	-0.88	0.81		0.82	0.75	0.93	-0.59	0.87	0.71	-0.68	0.84	0.91	0.76	0.93	-0.43	0.83	0.36	0.92
Non Current Assets Total	0.69	-0.08	0.62	0.6	0.7	0.68	-0.43	-0.84	-0.59	0.96	0.82		0.97	0.69	-0.41	0.62	0.25	-0.46	0.43	0.63	0.54	0.69	-0.25	0.48	0.59	0.64
Non Currrent Assets Other	0.57	-0.17	0.5	0.51	0.57	0.53	-0.35	-0.79	-0.45	0.98	0.75	0.97		0.57	-0.33	0.48	0.12	-0.39	0.33	0.49	0.41	0.56	-0.24	0.35	0.6	0.52
Cash And Short Term Investments	1.0	0.25	0.99	0.66	1.0	0.94	-0.4	-0.87	-0.98	0.61	0.93	0.69	0.57		-0.61	0.98	0.82	-0.65	0.85	0.99	0.85	1.0	-0.38	0.86	0.21	0.96
Net Receivables	-0.61	0.15	-0.66	-0.2	-0.63	-0.48	-0.08	0.62	0.65	-0.4	-0.59	-0.41	-0.33	-0.61		-0.58	-0.48	0.82	-0.65	-0.64	-0.36	-0.61	0.57	-0.7	0.07	-0.61
Common Stock Shares Outstanding	0.98	0.34	0.97	0.67	0.98	0.96	-0.39	-0.79	-0.96	0.53	0.87	0.62	0.48	0.98	-0.58		0.86	-0.56	0.84	0.98	0.87	0.98	-0.32	0.86	0.16	0.96
Non Current Liabilities Total	0.82	0.45	0.83	0.43	0.81	0.73	-0.02	-0.6	-0.83	0.21	0.71	0.25	0.12	0.82	-0.48	0.86		-0.47	0.91	0.86	0.77	0.82	-0.32	0.88	-0.1	0.89
Inventory	-0.65	0.06	-0.69	-0.34	-0.66	-0.46	-0.04	0.69	0.73	-0.46	-0.68	-0.46	-0.39	-0.65	0.82	-0.56	-0.47		-0.72	-0.69	-0.46	-0.65	0.45	-0.72	-0.09	-0.63
Other Current Assets	0.85	0.28	0.85	0.44	0.84	0.7	0.09	-0.78	-0.87	0.45	0.84	0.43	0.33	0.85	-0.65	0.84	0.91	-0.72		0.89	0.74	0.85	-0.44	0.98	0.09	0.93
Other Stockholder Equity	0.99	0.27	0.98	0.63	0.99	0.93	-0.33	-0.84	-0.99	0.55	0.91	0.63	0.49	0.99	-0.64	0.98	0.86	-0.69	0.89		0.85	0.99	-0.39	0.91	0.19	0.97
Total Liab	0.85	0.71	0.82	0.9	0.82	0.84	-0.33	-0.6	-0.82	0.48	0.76	0.54	0.41	0.85	-0.36	0.87	0.77	-0.46	0.74	0.85		0.85	0.14	0.75	0.27	0.85
Total Current Assets	1.0	0.25	0.99	0.66	1.0	0.94	-0.39	-0.86	-0.98	0.6	0.93	0.69	0.56	1.0	-0.61	0.98	0.82	-0.65	0.85	0.99	0.85		-0.38	0.86	0.2	0.96
Short Term Debt	-0.38	0.7	-0.41	0.42	-0.42	-0.23	-0.12	0.57	0.4	-0.25	-0.43	-0.25	-0.24	-0.38	0.57	-0.32	-0.32	0.45	-0.44	-0.39	0.14	-0.38		-0.42	0.18	-0.37
Common Stock	0.86	0.28	0.85	0.47	0.85	0.75	0.04	-0.77	-0.87	0.48	0.83	0.48	0.35	0.86	-0.7	0.86	0.88	-0.72	0.98	0.91	0.75	0.86	-0.42		0.15	0.94
Other Assets	0.21	0.12	0.08	0.42	0.2	0.29	-0.43	-0.35	-0.1	0.6	0.36	0.59	0.6	0.21	0.07	0.16	-0.1	-0.09	0.09	0.19	0.27	0.2	0.18	0.15		0.21
Net Tangible Assets	0.96	0.31	0.94	0.62	0.95	0.89	-0.19	-0.85	-0.93	0.61	0.92	0.64	0.52	0.96	-0.61	0.96	0.89	-0.63	0.93	0.97	0.85	0.96	-0.37	0.94	0.21

Click cells to compare fundamentals

Viridian Therapeutics Account Relationship Matchups

Viridian Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	30.3M	131.3M	203.7M	435.1M	490.4M	514.9M
Short Long Term Debt Total	8.3M	455K	520K	5.3M	21.0M	22.1M
Other Current Liab	5.1M	9.2M	10.5M	18.2M	23.3M	24.4M
Total Current Liabilities	10.2M	10.7M	13.6M	33.3M	26.6M	28.0M
Total Stockholder Equity	15.8M	120.0M	187.7M	395.1M	442.0M	464.1M
Property Plant And Equipment Net	523K	787K	2.1M	2.9M	3.3M	3.5M
Current Deferred Revenue	5.0M	301K	289K	288K	259.2K	246.2K
Net Debt	(16.5M)	(45.4M)	(41.8M)	(150.3M)	(81.8M)	(77.7M)
Retained Earnings	(168.2M)	(278.9M)	(358.3M)	(488.2M)	(725.9M)	(689.6M)
Accounts Payable	1.1M	670K	2.3M	14.2M	2.2M	2.1M
Cash	24.8M	45.9M	42.3M	155.6M	102.8M	108.0M
Non Current Assets Total	523K	1.6M	3.5M	10.5M	3.9M	2.5M
Non Currrent Assets Other	(523K)	857K	1.5M	7.6M	604K	1.0M
Cash And Short Term Investments	26.8M	127.6M	197.0M	424.6M	477.4M	501.2M
Net Receivables	24K	108K	451K	102K	91.8K	87.2K
Common Stock Shares Outstanding	2.1M	3.6M	11.9M	32.1M	44.8M	47.0M
Liabilities And Stockholders Equity	30.3M	131.3M	203.7M	435.1M	490.4M	514.9M
Non Current Liabilities Total	4.3M	544K	2.4M	6.7M	21.8M	22.9M
Other Current Assets	5.4M	2.0M	2.6M	6.5M	9.0M	9.5M
Other Stockholder Equity	183.6M	218.1M	412.1M	741.1M	960.5M	1.0B
Total Liab	14.5M	11.2M	16.0M	40.0M	48.4M	50.8M
Total Current Assets	29.7M	129.6M	200.2M	424.6M	486.5M	510.8M
Short Term Debt	4.0M	455K	520K	613K	843K	800.9K
Common Stock	349K	42K	239K	414K	540K	567K
Net Tangible Assets	15.8M	(60.8M)	53.9M	252.9M	290.9M	305.4M
Capital Surpluse	131.9M	177.3M	183.6M	218.1M	250.8M	157.5M
Property Plant Equipment	523K	787K	2.1M	2.9M	3.4M	3.5M
Short Term Investments	2.0M	81.7M	154.7M	269.0M	374.5M	393.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Viridian Stock Analysis

When running Viridian Therapeutics' price analysis, check to measure Viridian Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viridian Therapeutics is operating at the current time. Most of Viridian Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viridian Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viridian Therapeutics' price. Additionally, you may evaluate how the addition of Viridian Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Viridian Current Deferred Revenue vs Cash Analysis

Current Deferred Revenue vs Cash

Current Deferred Revenue vs Cash Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Cash

Viridian Therapeutics fundamental ratios Correlations

Viridian Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Viridian Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Viridian Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments

Other Stockholder Equity	- 0.99	Retained Earnings
Retained Earnings	- 0.99	Other Current Liab
Total Current Assets	- 0.98	Retained Earnings
Cash And Short Term Investments	- 0.98	Retained Earnings
Cash	- 0.98	Net Debt
Retained Earnings	- 0.98	Total Stockholder Equity